SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Douglas D. Fang, Bin Zhang, Qingyang Gu, Maruja Lira, Qiang Xu, Hongye Sun, Maoxiang Qian, Weiqi Sheng, Mark Ozeck, Zhenxiong Wang, Cathy Zhang, Xinsheng Chen, Kevin X. Chen, Jian Li, Shu-Hui Chen, James Christensen, Mao Mao, Chi-Chung Chan, HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib, Journal of Thoracic Oncology, 2014, 9, 3, 285

    CrossRef

  2. 2
    Lorena Lobo de Figueiredo-Pontes, Daisy Wing-Sze Wong, Vicky Pui-Chi Tin, Lap-Ping Chung, Hiroyuki Yasuda, Norihiro Yamaguchi, Sohei Nakayama, Pasi Antero Jänne, Maria Pik Wong, Susumu Soeda Kobayashi, Daniel Botelho Costa, Identification and Characterization of ALK Kinase Splicing Isoforms in Non–Small-Cell Lung Cancer, Journal of Thoracic Oncology, 2014, 9, 2, 248

    CrossRef

  3. 3
    Georg Hutarew, Cornelia Hauser-Kronberger, Felix Strasser, Ida C Llenos, Otto Dietze, Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALKFISH, Histopathology, 2014, 65, 1
  4. 4
    Y. Yu, X.-Y. Wang, L. Sun, Y.-L. Wang, Y.-F. Wan, X.-Q. Li, Y.-M. Feng, Inhibition of KIF22 suppresses cancer cell proliferation by delaying mitotic exit through upregulating CDC25C expression, Carcinogenesis, 2014, 35, 6, 1416

    CrossRef

  5. 5
    Robert Roskoski, Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition, Pharmacological Research, 2013, 68, 1, 68

    CrossRef

  6. 6
    Renato Franco, Gaetano Rocco, Federica Zito Marino, Giuseppe Pirozzi, Nicola Normanno, Alessandro Morabito, Pasquale Sperlongano, Paola Stiuso, Amalia Luce, Gerardo Botti, Michele Caraglia, Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?, Expert Review of Anticancer Therapy, 2013, 13, 4, 407

    CrossRef

  7. 7
    Sacha I. Rothschild, Oliver Gautschi, Crizotinib in the Treatment of Non–Small-Cell Lung Cancer, Clinical Lung Cancer, 2013, 14, 5, 473

    CrossRef

  8. 8
    Soyeon Kim, Tae Min Kim, Dong-Wan Kim, Heounjeong Go, Bhumsuk Keam, Se-Hoon Lee, Ja-Lok Ku, Doo Hyun Chung, Dae Seog Heo, Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer, Journal of Thoracic Oncology, 2013, 8, 4, 415

    CrossRef

  9. 9
    Sara Pilotto, Umberto Peretti, Silvia Novello, Giulio Rossi, Michele Milella, Matteo Giaj Levra, Ludovica Ciuffreda, Francesco Massari, Matteo Brunelli, Giampaolo Tortora, Emilio Bria, PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine, Expert Opinion on Pharmacotherapy, 2013, 14, 5, 597

    CrossRef

  10. 10
    Helmut H. Popper, Ulrike Gruber-Moesenbacher, Leonhard Müllauer, Georg Hutarew, Michael Vesely, Robert Pirker, Wolfgang Hilbe, Ferdinand Ploner, Ulrike Setinek, Wolfgang Hulla, Hans Maier, William Sterlacci, Klaus Kirchbacher, Rainer Kolb, Maximilian Hochmair, Gerald Webersinke, Elvira Stacher, Patricia Grabher, Tamara Hernler, Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer, memo - Magazine of European Medical Oncology, 2013, 6, 2, 83

    CrossRef

  11. 11
    Marjan Harmsma, Bert Schutte, Frans C.S. Ramaekers, Serum markers in small cell lung cancer: Opportunities for improvement, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2013, 1836, 2, 255

    CrossRef

  12. 12
    Alice T. Shaw, Peggy P. Hsu, Mark M. Awad, Jeffrey A. Engelman, Tyrosine kinase gene rearrangements in epithelial malignancies, Nature Reviews Cancer, 2013, 13, 11, 772

    CrossRef

  13. 13
    Ciara Kelly, Catherine M Kelly, Understanding molecular pathways and the identification of subgroups of patients with specific biomarker predictors of drug response related to orphan drugs, Expert Opinion on Orphan Drugs, 2013, 1, 1, 67

    CrossRef

  14. 14
    Ciara Kelly, Catherine M Kelly, Understanding molecular pathways and the identification of subgroups of patients with specific biomarker predictors of drug response related to orphan drugs, Expert Opinion on Orphan Drugs, 2013, 1, 1, 67

    CrossRef

  15. 15
    Julien Vincenten, Egbert F Smit, Bauke Ylstra, Erik Thunnissen, Applying biomarker testing to clinical practice in lung cancer, Lung Cancer Management, 2012, 1, 2, 145

    CrossRef

  16. 16
    Patrick M Forde, Charles M Rudin, Crizotinib in the treatment of non-small-cell lung cancer, Expert Opinion on Pharmacotherapy, 2012, 13, 8, 1195

    CrossRef

  17. 17
    Eunhee S. Yi, Jin-Haeng Chung, Kimary Kulig, Keith M. Kerr, Detection of Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Non-Small Cell Lung Cancer and Related Issues in ALK Inhibitor Therapy, Molecular Diagnosis & Therapy, 2012, 16, 3, 143

    CrossRef

  18. 18
    Lu-Lu Yang, Yi-Long Wu, Gene fusions in non-small-cell lung cancer, Lung Cancer Management, 2012, 1, 4, 283

    CrossRef

  19. 19
    Pierre-Alexandre Just, Aurélie Cazes, Anne Audebourg, Anatole Cessot, Karine Pallier, Claire Danel, Marie-Cécile Vacher-Lavenu, Pierre Laurent-Puig, Benoît Terris, Hélène Blons, Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers, Lung Cancer, 2012, 76, 3, 309

    CrossRef

  20. 20
    Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan, Amy Donahue, Sean R Downing, Garrett M Frampton, Lazaro Garcia, Frank Juhn, Kathy C Mitchell, Emily White, Jared White, Zac Zwirko, Tamar Peretz, Hovav Nechushtan, Lior Soussan-Gutman, Jhingook Kim, Hidefumi Sasaki, Hyeong Ryul Kim, Seung-il Park, Dalia Ercan, Christine E Sheehan, Jeffrey S Ross, Maureen T Cronin, Pasi A Jänne, Philip J Stephens, Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies, Nature Medicine, 2012, 18, 3, 382

    CrossRef

  21. 21
    Oliver Rath, Frank Kozielski, Kinesins and cancer, Nature Reviews Cancer, 2012, 12, 8, 527

    CrossRef

  22. 22
    Philip T. Cagle, Jeffrey Myers, Precision Medicine for Lung Cancer: Role of the Surgical Pathologist, Archives of Pathology & Laboratory Medicine, 2012, 136, 10, 1186

    CrossRef

  23. 23
    Andres Morales Madrid, Nicholas Campbell, Sonali Smith, Susan L. Cohn, Ravi Salgia, Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma, Targeted Oncology, 2012, 7, 3, 199

    CrossRef

  24. 24
    Ping Yang, Kimary Kulig, Jennifer M. Boland, Michele R. Erickson-Johnson, Andre M. Oliveira, Jason Wampfler, Aminah Jatoi, Claude Deschamps, Randolph Marks, Connie Fortner, Shawn Stoddard, Francis Nichols, Julian Molina, Marie-Christine Aubry, Hui Tang, Eunhee S. Yi, Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma, Journal of Thoracic Oncology, 2012, 7, 1, 90

    CrossRef

  25. 25
    Marcello Tiseo, Francesco Gelsomino, Marco Bartolotti, Paola Bordi, Melissa Bersanelli, Giulio Rossi, Andrea Ardizzoni, Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer, Expert Review of Anticancer Therapy, 2011, 11, 11, 1677

    CrossRef

  26. 26
    Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima, Tatsushi Kodama, Takamitsu Kobayashi, Takaaki A. Fukami, Nobuhiro Oikawa, Takuo Tsukuda, Nobuya Ishii, Yuko Aoki, CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant, Cancer Cell, 2011, 19, 5, 679

    CrossRef